http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 04 Sep 2026 06:04:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protalix+BioTherapeutics++For%3A+Sep+03++Filed+by%3A+Bar-Shalev+Amos/27027307.html si-local-file:///var/storage/secattach/20260904/27027307.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protalix+BioTherapeutics++For%3A+Sep+03++Filed+by%3A+Bar-Shalev+Amos/27027307.html Fri, 04 Sep 2026 06:04:00 -0400 PLX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protalix+BioTherapeutics++For%3A+Sep+03++Filed+by%3A+Forster+Eliot/27027316.html si-local-file:///var/storage/secattach/20260904/27027316.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protalix+BioTherapeutics++For%3A+Sep+03++Filed+by%3A+Forster+Eliot/27027316.html Fri, 04 Sep 2026 06:04:00 -0400 PLX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protalix+BioTherapeutics++For%3A+Sep+03++Filed+by%3A+Melincoff+Gwen+A/27027318.html si-local-file:///var/storage/secattach/20260904/27027318.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protalix+BioTherapeutics++For%3A+Sep+03++Filed+by%3A+Melincoff+Gwen+A/27027318.html Fri, 04 Sep 2026 06:04:00 -0400 PLX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protalix+BioTherapeutics++For%3A+Sep+03++Filed+by%3A+Boudes+Pol+F/27027321.html si-local-file:///var/storage/secattach/20260904/27027321.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protalix+BioTherapeutics++For%3A+Sep+03++Filed+by%3A+Boudes+Pol+F/27027321.html Fri, 04 Sep 2026 06:04:00 -0400 PLX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protalix+BioTherapeutics++For%3A+Sep+03++Filed+by%3A+Bashan+Dror/27027322.html si-local-file:///var/storage/secattach/20260904/27027322.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protalix+BioTherapeutics++For%3A+Sep+03++Filed+by%3A+Bashan+Dror/27027322.html Fri, 04 Sep 2026 06:04:00 -0400 PLX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protalix+BioTherapeutics++For%3A+Sep+03++Filed+by%3A+Ben+Zvi+Shmuel/27027323.html si-local-file:///var/storage/secattach/20260904/27027323.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protalix+BioTherapeutics++For%3A+Sep+03++Filed+by%3A+Ben+Zvi+Shmuel/27027323.html Fri, 04 Sep 2026 06:04:00 -0400 PLX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protalix+BioTherapeutics++For%3A+Sep+03++Filed+by%3A+Naos+Yaron/27027325.html si-local-file:///var/storage/secattach/20260904/27027325.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protalix+BioTherapeutics++For%3A+Sep+03++Filed+by%3A+Naos+Yaron/27027325.html Fri, 04 Sep 2026 06:04:00 -0400 PLX http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protalix+BioTherapeutics++For%3A+Sep+03++Filed+by%3A+Elze+Christian/27027337.html si-local-file:///var/storage/secattach/20260904/27027337.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Protalix+BioTherapeutics++For%3A+Sep+03++Filed+by%3A+Elze+Christian/27027337.html Fri, 04 Sep 2026 06:04:00 -0400 PLX http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Protalix+BioTherapeutics+++++++++++++/26908993.html si-local-file:///var/storage/secattach/20260812/26908993.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Protalix+BioTherapeutics+++++++++++++/26908993.html Wed, 12 Aug 2026 07:41:00 -0400 O.02989433 PLX http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Protalix+BioTherapeutics+++++++++++++/26908993.html si-local-file:///var/storage/secattach/20260812/26908993.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++Protalix+BioTherapeutics+++++++++++++/26908993.html Wed, 12 Aug 2026 07:41:00 -0400 O.02989433 PLX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Protalix+BioTherapeutics++For%3A+Jun+30/26908816.html si-local-file:///var/storage/secattach/20260812/26908816.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Protalix+BioTherapeutics++For%3A+Jun+30/26908816.html Wed, 12 Aug 2026 07:10:00 -0400 O.02989433 PLX http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Protalix+BioTherapeutics++For%3A+Jun+30/26908816.html si-local-file:///var/storage/secattach/20260812/26908816.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Protalix+BioTherapeutics++For%3A+Jun+30/26908816.html Wed, 12 Aug 2026 07:10:00 -0400 O.02989433 PLX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Protalix+BioTherapeutics++For%3A+Aug+12/26908707.html si-local-file:///var/storage/secattach/20260812/26908707.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Protalix+BioTherapeutics++For%3A+Aug+12/26908707.html Wed, 12 Aug 2026 07:00:00 -0400 O.02989433 PLX http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Protalix+BioTherapeutics++For%3A+Aug+12/26908707.html si-local-file:///var/storage/secattach/20260812/26908707.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++Protalix+BioTherapeutics++For%3A+Aug+12/26908707.html Wed, 12 Aug 2026 07:00:00 -0400 O.02989433 PLX http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast today at <chron>8:00 a.m. EDT</chron></i></p><ul type="disc"><li>Revenues <span>from selling goods </span>increased to <money>$19.8 million</money> in the second quarter of 2026, up <money>$4.4 million</money> from the second quarter of 2025, driven primarily by sales of Elfabrio^{®<br /><br />}</li><li>Total revenue climbed to <money>$53.6 million</money>, year to date, from <money>$25.8 million</money> for the same period in 2025, which includes the previously reported <money>$25.0 million</money> Chiesi milestone payment<br /><br /></li><li>Year-to-date, the Company achieved profitability with a net income of <money>$22.1 million</money><br /><br /></li><li>The Company reiterates full-year 2026 guidance of <money>$78.0 million</money> to <money>$83.0 million</money> in total revenue<br http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html Wed, 12 Aug 2026 06:50:00 -0400 A.01908724 A.06822034 A.31066700 A.31523649 A.38474826 A.50200961 A.50216777 O.00532504 O.01383535 O.02989433 O.20026344 O.20988509 O.22422661 O.29413480 O.54516537 PBDA PBDA PBDA PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast today at <chron>8:00 a.m. EDT</chron></i></p><ul type="disc"><li>Revenues <span>from selling goods </span>increased to <money>$19.8 million</money> in the second quarter of 2026, up <money>$4.4 million</money> from the second quarter of 2025, driven primarily by sales of Elfabrio^{®<br /><br />}</li><li>Total revenue climbed to <money>$53.6 million</money>, year to date, from <money>$25.8 million</money> for the same period in 2025, which includes the previously reported <money>$25.0 million</money> Chiesi milestone payment<br /><br /></li><li>Year-to-date, the Company achieved profitability with a net income of <money>$22.1 million</money><br /><br /></li><li>The Company reiterates full-year 2026 guidance of <money>$78.0 million</money> to <money>$83.0 million</money> in total revenue<br http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html Wed, 12 Aug 2026 06:50:00 -0400 A.01908724 A.06822034 A.31066700 A.31523649 A.38474826 A.50200961 A.50216777 O.00532504 O.01383535 O.02989433 O.20026344 O.20988509 O.22422661 O.29413480 O.54516537 PBDA PBDA PBDA PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast today at <chron>8:00 a.m. EDT</chron></i></p><ul type="disc"><li>Revenues <span>from selling goods </span>increased to <money>$19.8 million</money> in the second quarter of 2026, up <money>$4.4 million</money> from the second quarter of 2025, driven primarily by sales of Elfabrio^{®<br /><br />}</li><li>Total revenue climbed to <money>$53.6 million</money>, year to date, from <money>$25.8 million</money> for the same period in 2025, which includes the previously reported <money>$25.0 million</money> Chiesi milestone payment<br /><br /></li><li>Year-to-date, the Company achieved profitability with a net income of <money>$22.1 million</money><br /><br /></li><li>The Company reiterates full-year 2026 guidance of <money>$78.0 million</money> to <money>$83.0 million</money> in total revenue<br http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html Wed, 12 Aug 2026 06:50:00 -0400 A.01908724 A.06822034 A.31066700 A.31523649 A.38474826 A.50200961 A.50216777 O.00532504 O.01383535 O.02989433 O.20026344 O.20988509 O.22422661 O.29413480 O.54516537 PBDA PBDA PBDA PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast today at <chron>8:00 a.m. EDT</chron></i></p><ul type="disc"><li>Revenues <span>from selling goods </span>increased to <money>$19.8 million</money> in the second quarter of 2026, up <money>$4.4 million</money> from the second quarter of 2025, driven primarily by sales of Elfabrio^{®<br /><br />}</li><li>Total revenue climbed to <money>$53.6 million</money>, year to date, from <money>$25.8 million</money> for the same period in 2025, which includes the previously reported <money>$25.0 million</money> Chiesi milestone payment<br /><br /></li><li>Year-to-date, the Company achieved profitability with a net income of <money>$22.1 million</money><br /><br /></li><li>The Company reiterates full-year 2026 guidance of <money>$78.0 million</money> to <money>$83.0 million</money> in total revenue<br http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html Wed, 12 Aug 2026 06:50:00 -0400 A.01908724 A.06822034 A.31066700 A.31523649 A.38474826 A.50200961 A.50216777 O.00532504 O.01383535 O.02989433 O.20026344 O.20988509 O.22422661 O.29413480 O.54516537 PBDA PBDA PBDA PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast today at <chron>8:00 a.m. EDT</chron></i></p><ul type="disc"><li>Revenues <span>from selling goods </span>increased to <money>$19.8 million</money> in the second quarter of 2026, up <money>$4.4 million</money> from the second quarter of 2025, driven primarily by sales of Elfabrio^{®<br /><br />}</li><li>Total revenue climbed to <money>$53.6 million</money>, year to date, from <money>$25.8 million</money> for the same period in 2025, which includes the previously reported <money>$25.0 million</money> Chiesi milestone payment<br /><br /></li><li>Year-to-date, the Company achieved profitability with a net income of <money>$22.1 million</money><br /><br /></li><li>The Company reiterates full-year 2026 guidance of <money>$78.0 million</money> to <money>$83.0 million</money> in total revenue<br http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html Wed, 12 Aug 2026 06:50:00 -0400 A.01908724 A.06822034 A.31066700 A.31523649 A.38474826 A.50200961 A.50216777 O.00532504 O.01383535 O.02989433 O.20026344 O.20988509 O.22422661 O.29413480 O.54516537 PBDA PBDA PBDA PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast today at <chron>8:00 a.m. EDT</chron></i></p><ul type="disc"><li>Revenues <span>from selling goods </span>increased to <money>$19.8 million</money> in the second quarter of 2026, up <money>$4.4 million</money> from the second quarter of 2025, driven primarily by sales of Elfabrio^{®<br /><br />}</li><li>Total revenue climbed to <money>$53.6 million</money>, year to date, from <money>$25.8 million</money> for the same period in 2025, which includes the previously reported <money>$25.0 million</money> Chiesi milestone payment<br /><br /></li><li>Year-to-date, the Company achieved profitability with a net income of <money>$22.1 million</money><br /><br /></li><li>The Company reiterates full-year 2026 guidance of <money>$78.0 million</money> to <money>$83.0 million</money> in total revenue<br http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html Wed, 12 Aug 2026 06:50:00 -0400 A.01908724 A.06822034 A.31066700 A.31523649 A.38474826 A.50200961 A.50216777 O.00532504 O.01383535 O.02989433 O.20026344 O.20988509 O.22422661 O.29413480 O.54516537 PBDA PBDA PBDA PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast today at <chron>8:00 a.m. EDT</chron></i></p><ul type="disc"><li>Revenues <span>from selling goods </span>increased to <money>$19.8 million</money> in the second quarter of 2026, up <money>$4.4 million</money> from the second quarter of 2025, driven primarily by sales of Elfabrio^{®<br /><br />}</li><li>Total revenue climbed to <money>$53.6 million</money>, year to date, from <money>$25.8 million</money> for the same period in 2025, which includes the previously reported <money>$25.0 million</money> Chiesi milestone payment<br /><br /></li><li>Year-to-date, the Company achieved profitability with a net income of <money>$22.1 million</money><br /><br /></li><li>The Company reiterates full-year 2026 guidance of <money>$78.0 million</money> to <money>$83.0 million</money> in total revenue<br http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html Wed, 12 Aug 2026 06:50:00 -0400 A.01908724 A.06822034 A.31066700 A.31523649 A.38474826 A.50200961 A.50216777 O.00532504 O.01383535 O.02989433 O.20026344 O.20988509 O.22422661 O.29413480 O.54516537 PBDA PBDA PBDA PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast today at <chron>8:00 a.m. EDT</chron></i></p><ul type="disc"><li>Revenues <span>from selling goods </span>increased to <money>$19.8 million</money> in the second quarter of 2026, up <money>$4.4 million</money> from the second quarter of 2025, driven primarily by sales of Elfabrio^{®<br /><br />}</li><li>Total revenue climbed to <money>$53.6 million</money>, year to date, from <money>$25.8 million</money> for the same period in 2025, which includes the previously reported <money>$25.0 million</money> Chiesi milestone payment<br /><br /></li><li>Year-to-date, the Company achieved profitability with a net income of <money>$22.1 million</money><br /><br /></li><li>The Company reiterates full-year 2026 guidance of <money>$78.0 million</money> to <money>$83.0 million</money> in total revenue<br http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html Wed, 12 Aug 2026 06:50:00 -0400 A.01908724 A.06822034 A.31066700 A.31523649 A.38474826 A.50200961 A.50216777 O.00532504 O.01383535 O.02989433 O.20026344 O.20988509 O.22422661 O.29413480 O.54516537 PBDA PBDA PBDA PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast today at <chron>8:00 a.m. EDT</chron></i></p><ul type="disc"><li>Revenues <span>from selling goods </span>increased to <money>$19.8 million</money> in the second quarter of 2026, up <money>$4.4 million</money> from the second quarter of 2025, driven primarily by sales of Elfabrio^{®<br /><br />}</li><li>Total revenue climbed to <money>$53.6 million</money>, year to date, from <money>$25.8 million</money> for the same period in 2025, which includes the previously reported <money>$25.0 million</money> Chiesi milestone payment<br /><br /></li><li>Year-to-date, the Company achieved profitability with a net income of <money>$22.1 million</money><br /><br /></li><li>The Company reiterates full-year 2026 guidance of <money>$78.0 million</money> to <money>$83.0 million</money> in total revenue<br http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html Wed, 12 Aug 2026 06:50:00 -0400 A.01908724 A.06822034 A.31066700 A.31523649 A.38474826 A.50200961 A.50216777 O.00532504 O.01383535 O.02989433 O.20026344 O.20988509 O.22422661 O.29413480 O.54516537 PBDA PBDA PBDA PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast today at <chron>8:00 a.m. EDT</chron></i></p><ul type="disc"><li>Revenues <span>from selling goods </span>increased to <money>$19.8 million</money> in the second quarter of 2026, up <money>$4.4 million</money> from the second quarter of 2025, driven primarily by sales of Elfabrio^{®<br /><br />}</li><li>Total revenue climbed to <money>$53.6 million</money>, year to date, from <money>$25.8 million</money> for the same period in 2025, which includes the previously reported <money>$25.0 million</money> Chiesi milestone payment<br /><br /></li><li>Year-to-date, the Company achieved profitability with a net income of <money>$22.1 million</money><br /><br /></li><li>The Company reiterates full-year 2026 guidance of <money>$78.0 million</money> to <money>$83.0 million</money> in total revenue<br http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html Wed, 12 Aug 2026 06:50:00 -0400 A.01908724 A.06822034 A.31066700 A.31523649 A.38474826 A.50200961 A.50216777 O.00532504 O.01383535 O.02989433 O.20026344 O.20988509 O.22422661 O.29413480 O.54516537 PBDA PBDA PBDA PLX US74365A30 http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html <div class="xn-content"> <p class="prntac"><i>Company to host conference call and webcast today at <chron>8:00 a.m. EDT</chron></i></p><ul type="disc"><li>Revenues <span>from selling goods </span>increased to <money>$19.8 million</money> in the second quarter of 2026, up <money>$4.4 million</money> from the second quarter of 2025, driven primarily by sales of Elfabrio^{®<br /><br />}</li><li>Total revenue climbed to <money>$53.6 million</money>, year to date, from <money>$25.8 million</money> for the same period in 2025, which includes the previously reported <money>$25.0 million</money> Chiesi milestone payment<br /><br /></li><li>Year-to-date, the Company achieved profitability with a net income of <money>$22.1 million</money><br /><br /></li><li>The Company reiterates full-year 2026 guidance of <money>$78.0 million</money> to <money>$83.0 million</money> in total revenue<br http://www.streetinsider.com/Press+Releases/Protalix+BioTherapeutics+Reports+Second+Quarter+2026+Financial+and+Business+Results/26908604.html Wed, 12 Aug 2026 06:50:00 -0400 A.01908724 A.06822034 A.31066700 A.31523649 A.38474826 A.50200961 A.50216777 O.00532504 O.01383535 O.02989433 O.20026344 O.20988509 O.22422661 O.29413480 O.54516537 PBDA PBDA PBDA PLX US74365A30